The FDA enforcement report lists a class II recall, dated 14 October 2026, of compounded tirzepatide injection 18 mg/mL in 4 mL multi-dose vials from a US compounding pharmacy, on grounds of lack of assurance of sterility. The recall is ongoing. The same report carries separate class II recalls of compounded tirzepatide and semaglutide combined with cyanocobalamin from another compounder, for the same reason.
A class II recall means use could cause temporary or medically reversible harm, or that serious harm is remote. These are compounded products, not the licensed manufacturer's pens.
The India angle is indirect: compounded incretins are not a recognised supply route here, but patients increasingly buy injectable weight-loss products online or abroad. Ask where the product came from.
- Ask every patient on a GLP-1 or dual agonist where they obtain it.
- Treat injection-site infection or fever in a patient using a compounded incretin as a possible product problem.
- Report suspected contamination to the national pharmacovigilance programme.
- Licensed manufacturer pens are not part of this recall.
Why it matters
Demand for incretins has created an unlicensed supply chain whose quality nobody checks for you.
Don't overread it
A sterility-assurance recall is a manufacturing finding, not a report of patient harm.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free